# Sermorelin — Research Peptide Profile

> Sermorelin (Geref) won FDA approval for pediatric GH deficiency before its discontinuation (not safety-related). Mechanism, 10–20 min half-life & research dosing.

Source: https://peptpedia.org/peptide/sermorelin | Published: 2025-12-02 | Last updated: 2026-08-04

Sermorelin is a 29-amino-acid GHRH fragment that stimulates the pituitary's own GH production. It held FDA approval as Geref for pediatric GH deficiency from 1997 until the manufacturer discontinued it in 2008 — not for safety reasons — and is now available mainly as a compounded drug. Its human evidence base is among the oldest of any GH peptide.

## Overview

Sermorelin is a synthetic 29-amino-acid fragment of [endogenous growth hormone releasing hormone (GHRH)](/peptide/mod-grf-1-29) that retains full GHRHR agonist activity. It received FDA approval for pediatric GH deficiency diagnosis and treatment, though it was withdrawn from the US market around 2008 for commercial rather than safety reasons. Multiple randomized controlled trials in elderly adults document improved GH/[IGF-1](/peptide/igf-1-lr3) and body composition. Its ~10–20 minute half-life makes nightly dosing optimal, and unlike exogenous GH, Sermorelin preserves physiological pituitary negative feedback.

## Molecular Profile

- **Category:** growth-factors
- **Molecular formula:** C149H246N44O42S
- **Molecular weight:** 3357.88 g/mol
- **CAS number:** 86168-78-7
- **Amino acid sequence:** Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
- **Also known as:** Geref, GRF 1-29, GHRH(1-29)NH2
- **Half-life:** 10-20 minutes
- **Solubility:** Soluble in water
- **Storage:** Store lyophilized at -20°C. Reconstituted at 2-8°C.

## Mechanism of Action

Sermorelin binds to and activates the [GHRH receptor](/research/sermorelin-ghrh-receptor-pharmacology) on pituitary somatotroph cells, stimulating synthesis and release of growth hormone. This preserves the natural pulsatile pattern of GH release and maintains pituitary function. The negative feedback from IGF-1 remains intact, reducing the risk of excessive GH levels.

## Key Research Findings

- Sermorelin held FDA approval as Geref for diagnosing and treating pediatric growth hormone deficiency from 1997 until the manufacturer discontinued it in 2008; the FDA determined it was not withdrawn for safety or effectiveness reasons.
- Unlike exogenous growth hormone injections that suppress natural production, Sermorelin preserves pituitary function and the natural IGF-1 feedback loop, reducing the risk of excessive GH levels.
- Sermorelin contains only the first 29 amino acids of the 44 amino acid GHRH molecule, yet this fragment retains full biological activity at the GHRH receptor.
- Research shows Sermorelin can actually restore youthful GH secretion patterns in older adults over time, suggesting it may rejuvenate pituitary responsiveness rather than simply override it.

## Sermorelin Pharmacokinetics: First-Generation GHRH Analog

Sermorelin has a plasma half-life of approximately 10-20 minutes, producing a rapid but brief GH-releasing pulse that closely mimics the endogenous pattern of hypothalamic GHRH release. This short half-life necessitates nightly administration to coincide with the physiological nocturnal GH secretion peak, and has been the primary pharmacokinetic limitation driving development of longer-acting GHRH analogs.

### Rapid Clearance Profile

- Plasma half-life of 10-20 minutes following subcutaneous injection — the peptide is cleared from circulation within approximately 1-2 hours of administration.
- Peak GH response occurs within 15-30 minutes of SC injection, with GH levels returning toward baseline within 2-3 hours as sermorelin is cleared.
- Bedtime administration is the standard research protocol, timed to amplify the natural nocturnal GH pulse that occurs during the first cycle of slow-wave deep sleep (approximately 60-90 minutes after sleep onset).
- The short half-life preserves the pulsatile nature of GH release — each injection produces a discrete GH secretory episode rather than sustained elevation, maintaining physiological pituitary feedback regulation.

### Comparison to Modern GHRH Analogs

- CJC-1295 with DAC (Drug Affinity Complex) largely replaced sermorelin in research protocols due to its dramatically longer half-life of 6-8 days versus sermorelin's 10-20 minutes, enabling weekly rather than daily dosing.
- Modified GRF 1-29 (CJC-1295 without DAC) offers an intermediate half-life of approximately 30 minutes — still short but roughly double that of sermorelin, with amino acid substitutions at positions 2, 8, 15, and 27 for enhanced stability.
- Sermorelin retains advantages in specific research contexts: its rapid clearance more closely mimics physiological GHRH pulsatility, and its FDA approval history (Geref, approved for pediatric GH deficiency) provides a clinical safety dataset that longer-acting analogs lack.
- Despite its pharmacokinetic limitations, sermorelin remains the most extensively studied GHRH analog in human clinical trials, including multiple RCTs in elderly adults documenting improved body composition and nocturnal GH secretion patterns.

## Dosing Information (Research Context)

Clinical protocols have used dosages of 200-500 mcg daily, typically administered subcutaneously before bedtime to align with natural GH secretion patterns.

| Route | Dose | Frequency | Notes |
| --- | --- | --- | --- |
| Subcutaneous | 200–500 mcg | Once nightly | Bedtime dosing aligns with physiological GH peak; most studied protocol |
| Subcutaneous (pediatric) | 20–30 mcg/kg | Once nightly | FDA-approved pediatric GH deficiency protocol |

## Researched Effects

- **Physiological GH Release** (evidence: extensive): Sermorelin stimulates natural, pulsatile growth hormone release from the pituitary gland by binding to GHRH receptors on somatotroph cells, triggering intracellular signaling cascades that promote both GH synthesis and secretion in a dose-dependent manner. Clinical studies have documented peak GH concentrations occurring 30-60 minutes after administration, with levels increasing 3-10 fold above baseline depending on individual pituitary responsiveness and dosage protocols. Unlike exogenous GH administration which suppresses endogenous production, Sermorelin-stimulated growth hormone secretion maintains physiological feedback regulation through IGF-1, preventing excessive hormone levels while preserving the normal circadian rhythm of GH release characterized by nighttime pulses. Research demonstrates that Sermorelin therapy can restore youthful GH secretion patterns in adults with age-related decline, with studies showing improved GH response over time as pituitary function is maintained rather than suppressed. These physiological GH stimulation properties make Sermorelin particularly valuable for growth hormone deficiency research, anti-aging medicine investigations, and developing GHRH-based therapeutic approaches that work with the body's natural regulatory mechanisms.
- **IGF-1 Elevation** (evidence: extensive): Research demonstrates Sermorelin's ability to significantly increase insulin-like growth factor-1 (IGF-1) levels through sustained stimulation of endogenous growth hormone production from the pituitary gland. Clinical trials have documented IGF-1 elevations of 20-40% above baseline within 4-12 weeks of consistent Sermorelin administration, with levels stabilizing within the normal physiological range rather than reaching supraphysiological concentrations associated with exogenous GH therapy. Studies indicate that IGF-1 increases correlate with improvements in body composition including reduced visceral adiposity and increased lean muscle mass, reflecting the anabolic effects mediated through GH-induced hepatic IGF-1 synthesis. The sustained IGF-1 elevation achieved through Sermorelin therapy has been associated with improvements in skin elasticity, bone mineral density markers, and exercise recovery metrics in clinical research settings. These IGF-1 optimization properties position Sermorelin as an important research tool for investigating growth hormone axis restoration, age-related decline in anabolic hormone function, and the relationship between IGF-1 levels and metabolic health outcomes.
- **Pituitary Function Preservation** (evidence: moderate): Research indicates Sermorelin may help maintain or restore pituitary growth hormone production capacity through regular physiological stimulation of somatotroph cells, potentially reversing age-related decline in GH secretory reserve. Studies in elderly subjects demonstrate that chronic Sermorelin administration can improve pituitary responsiveness to GHRH stimulation over time, suggesting trophic effects on GH-producing cells that preserve their functional capacity. Unlike direct GH replacement which causes pituitary suppression through negative feedback, Sermorelin-based therapy appears to exercise the pituitary, maintaining cellular health and hormone synthetic machinery for endogenous production. Research has documented improved GH release in response to standardized provocative testing after extended Sermorelin treatment periods, indicating enhanced pituitary reserve function compared to untreated age-matched controls. These pituitary function preservation properties have significant implications for pediatric growth hormone deficiency treatment, adult GH replacement strategies, and understanding the mechanisms of hypothalamic-pituitary axis aging in neuroendocrine research.
- **Sleep Quality Enhancement** (evidence: moderate): Clinical research suggests Sermorelin administration before bedtime may enhance sleep quality through its effects on growth hormone release during the critical first sleep cycles when natural GH secretion peaks. Studies indicate that GH-releasing hormone and its analogs including Sermorelin promote slow-wave deep sleep, the most restorative sleep phase associated with tissue repair, immune function optimization, and memory consolidation. Research has documented improvements in sleep efficiency, reduced sleep latency, and increased time spent in deep sleep stages following evening Sermorelin administration in adult subjects. The peptide's short half-life of 10-20 minutes allows it to stimulate the natural nighttime GH pulse without prolonged hormonal elevation that could disrupt sleep architecture. These sleep quality improvement properties position Sermorelin as a valuable research compound for investigating the relationship between growth hormone axis function and sleep physiology, age-related sleep disturbances, and potential therapeutic approaches to sleep disorders associated with declining GH secretion.

## Research Applications

- Endocrinology
- Pediatric Research
- Aging Studies
- GH Deficiency Research
- Sleep Medicine Research

## Key Studies

### Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?

Walker RF — *Clinical Interventions in Aging* (2006) — [PMID 18046908](https://pubmed.ncbi.nlm.nih.gov/18046908/) | [doi:10.2147/ciia.2006.1.4.307](https://doi.org/10.2147/ciia.2006.1.4.307)

This short editorial (a single-author commentary in Clinical Interventions in Aging; the PubMed record carries no abstract) argues for sermorelin—an analog of growth hormone-releasing hormone (GHRH 1-29)—as an approach to adult-onset growth hormone insufficiency. The author's central contention is mechanistic rather than trial-based: unlike exogenous recombinant GH, which drives hepatic IGF-1 production directly, sermorelin stimulates the patient's own pituitary by binding GHRH receptors to increase secretion of endogenous GH. He emphasizes that this endogenous secretion remains under negative-feedback control via somatostatin, so overdose is difficult to achieve, framing sermorelin as simulating more normal physiology and avoiding tachyphylaxis compared with continuous exogenous GH exposure. The piece is a viewpoint/commentary and does not present original clinical trial data on efficacy or safety outcomes.

### Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men

Vittone J, Blackman MR, et al. — *Metabolism* (1997) — [PMID 9005976](https://pubmed.ncbi.nlm.nih.gov/9005976/) | [doi:10.1016/s0026-0495(97)90174-8](https://doi.org/10.1016/s0026-0495(97)90174-8)

This study examined whether single nightly injections of GHRH (1-29)—the peptide marketed as sermorelin—could sustain growth hormone and IGF-1 increases and improve muscle function in healthy elderly men. Eleven non-obese men aged 64–76 with low baseline IGF-1 self-administered 2 mg of GHRH subcutaneously each night for 6 weeks. Treatment significantly increased nocturnal GH secretion (mean release, peak amplitude, and area under the curve) but did not change serum IGF-1, IGFBP-3, or GH binding protein, and produced no change in body weight, BMI, or DEXA measures of muscle and fat. Two of six muscle-strength measures improved, with no adverse effects on glucose, insulin, or lipids. The authors concluded that single nightly GHRH dosing is less effective than multiple daily doses at eliciting GH/IGF-1-mediated effects—an important caveat for once-nightly sermorelin protocols.

### Continuous subcutaneous infusions of growth hormone (GH) releasing hormone 1-44 for 14 days increase GH and insulin-like growth factor-I levels in old men

Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR — *Journal of Clinical Endocrinology and Metabolism* (1993) — [PMID 8421077](https://pubmed.ncbi.nlm.nih.gov/8421077/) | [doi:10.1210/jcem.76.1.8421077](https://doi.org/10.1210/jcem.76.1.8421077)

This study investigated the effects of continuous subcutaneous GHRH 1-44 infusion over 14 days in healthy elderly men aged 64-76 years. Treatment produced significant increases in mean 24-hour GH levels and IGF-I concentrations, demonstrating that the aging pituitary retains the capacity to respond to sustained GHRH stimulation. However, the study notably found that continuous infusion decreased nocturnal peak GH amplitude and duration, suggesting that pulsatile rather than continuous GHRH delivery may be more physiological for restoring age-related GH decline. Despite this finding, the overall increase in integrated GH secretion and IGF-I levels confirmed that reduced hypothalamic GHRH stimulation, not pituitary failure, is a primary driver of age-related GH decline. These results informed subsequent research emphasizing pulsatile GHRH analog administration for optimal GH restoration in aging populations.

## Frequently Asked Questions

### How does Sermorelin differ from synthetic (exogenous) GH?

Synthetic GH directly replaces the hormone, bypasses the pituitary, and suppresses natural GH production via negative feedback—prolonged use can cause the pituitary to reduce its own GH output. Sermorelin stimulates the pituitary to produce GH through the natural GHRH receptor pathway, preserving the IGF-1 negative feedback loop. This means GH release remains self-regulated: as IGF-1 rises, it signals the hypothalamus to reduce GHRH output, automatically limiting GH excess. This feedback preservation is considered safer for long-term administration.

### Was Sermorelin actually FDA approved?

Yes. Sermorelin (brand name Geref) received FDA approval for diagnosing and treating idiopathic growth hormone deficiency in children with short stature. It was commercially available in the United States from the 1990s until approximately 2008, when the manufacturer (Serono) withdrew it from the US market for commercial (not safety) reasons. The FDA approval history gives Sermorelin one of the strongest clinical validation profiles among GHRH analogs, with a documented pediatric safety record.

### Why should Sermorelin be administered at bedtime?

Endogenous GH secretion follows a circadian rhythm, with the largest pulse occurring during the first cycle of slow-wave (deep) sleep, approximately 60–90 minutes after sleep onset. By administering Sermorelin at bedtime, the GHRH receptor stimulation coincides with this natural peak, amplifying rather than overriding the physiological pattern. This timing strategy produces higher GH responses than daytime administration and better mimics the body's natural GH secretion architecture. Research protocols consistently use bedtime administration for this reason.

### How does Sermorelin compare to CJC-1295?

Both are GHRH analogs activating the same pituitary receptor, but with very different pharmacokinetics. Sermorelin has a ~10–20 minute half-life, requiring daily injection and producing acute GH pulses. CJC-1295 with DAC has a 6–8 day half-life (due to albumin binding), enabling weekly dosing and sustaining continuous GH/IGF-1 elevation. Sermorelin better preserves natural pulsatility; CJC-1295 provides greater convenience. Sermorelin has more extensive human clinical data (including FDA approval); CJC-1295 has one published Phase I/II trial.

### Can Sermorelin restore pituitary function in older adults?

Research suggests yes, partially. A 1993 JCEM study by Corpas et al. (PMID: 8421077) found that continuous GHRH infusion increased overall GH and IGF-I levels in elderly men, demonstrating the aging pituitary retains capacity to respond to sustained GHRH stimulation. This supports a 'pituitary exercise' concept where GHRH analog administration maintains somatotroph responsiveness. This contrasts with exogenous GH, which tends to suppress pituitary activity. The implication is that Sermorelin may maintain or partially restore somatotroph population and function in aging individuals, though the evidence is limited to short-term studies.

### What body composition changes does Sermorelin research show in elderly adults?

Controlled data are more modest than often claimed. In a 6-week study of healthy elderly men (PMID: 9005976), nightly GHRH (1-29)—the sermorelin peptide—significantly increased nocturnal growth hormone secretion but did not change serum IGF-1 or DEXA-measured muscle and fat, though some measures of muscle strength improved; the authors concluded single nightly dosing is less effective than multiple daily doses. Larger or more frequent GHRH-analog regimens have reported small improvements in lean mass and fat, but body-composition effects are smaller and less consistent than with exogenous GH, reflecting sermorelin's self-regulated, feedback-limited mechanism.

### Why was Sermorelin withdrawn from the US market and is it still available?

Sermorelin (Geref) was withdrawn from the US market around 2008 by manufacturer Serono for commercial reasons, not safety concerns. The FDA approval itself was not withdrawn—the safety and efficacy record remains intact. Following Geref's discontinuation, Sermorelin entered widespread use in compounding pharmacy formulations for anti-aging and adult GH deficiency applications. Compounded Sermorelin is available from 503A pharmacy compounders with a prescription. Note: FDA has scrutinized certain compounded peptides; current availability should be verified with specific compounders. Outside the US, Sermorelin is available in several countries.

### How does Sermorelin affect IGF-1 levels?

Sermorelin's GH-stimulating effects cascade to increase hepatic IGF-1 production over weeks of treatment. Randomized studies show IGF-1 increases of 30–70% after 3–6 months of nightly Sermorelin. In GH-deficient adults and elderly individuals with below-normal IGF-1, this normalization toward younger reference ranges is the primary pharmacological goal. Monitoring IGF-1 every 6–12 weeks is standard in research protocols to assess response and adjust dosing. Unlike direct IGF-1 injection, Sermorelin's IGF-1 elevation is self-regulated by feedback mechanisms—if GH rises excessively, somatostatin release limits further stimulation.

## Related Peptides

- [CJC-1295](https://peptpedia.org/peptide/cjc-1295)
- [Ipamorelin](https://peptpedia.org/peptide/ipamorelin)
- [GHRP-6](https://peptpedia.org/peptide/ghrp-6)
- [Mod GRF 1-29](https://peptpedia.org/peptide/mod-grf-1-29)

---

This content is for educational and research purposes only. It is not medical advice, and the compounds covered are research chemicals not approved for human use unless explicitly stated otherwise.

Cite this page: Peptpedia — Research Peptide Encyclopedia, https://peptpedia.org